![]() | License: Creative Commons: Attribution 3.0 PDF - Published Version (4MB) |
- URN to cite this document:
- urn:nbn:de:bvb:355-epub-553783
- DOI to cite this document:
- 10.5283/epub.55378
Abstract
At present, targeting PD-1/PD-L1 axis for immune checkpoint inhibition has improved treatment of various tumor entities, including head and neck squamous cell carcinoma (HNSCC). However, one part of the patient cohort still shows little improvement or even hyperprogression. We established three radioresistant (RR) and three radiosensitive (RS) HNSCC cell lines. RR cells showed prolonged survival ...

Owner only: item control page